Evidence map›Paper›PMID 36604748›Full record

ArticleGenome medicine2023

The gut microbiota in multiple sclerosis varies with disease activity.

Florence Thirion, Finn Sellebjerg, Yong Fan, Liwei Lyu, Tue H Hansen, Nicolas Pons, Florence Levenez, Benoit Quinquis, Evelina Stankevic, Helle B Søndergaard and 10 more

Open access · goldAbstract read
In one paragraph

Article in Genome medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
81citing papers in PubMed, 3 pooled it
15.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 102 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Review
  12. Observational
  13. Significant changes in the fecal bacteriobiota richness and diversity in patients with relapsing-remitting multiple sclerosis compared to healthy individuals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Nutrients · 2026
    Article
  18. Female-enrichedbioRxiv : the preprint server for biology · 2026
    Article
  19. Article
  20. Review

21 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 5 countries.

Florence Thirion *Université Paris-Saclay, INRAE, MGP, 78350, Jouy-en-Josas, France.
Finn Sellebjerg *Danish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, 2600, Glostrup, Denmark.
Yong Fan *Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Liwei LyuNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Tue H HansenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Nicolas PonsUniversité Paris-Saclay, INRAE, MGP, 78350, Jouy-en-Josas, France.
Florence LevenezUniversité Paris-Saclay, INRAE, MGP, 78350, Jouy-en-Josas, France.
Benoit QuinquisUniversité Paris-Saclay, INRAE, MGP, 78350, Jouy-en-Josas, France.
Evelina StankevicNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Helle B SøndergaardDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, 2600, Glostrup, Denmark.
Thomas M DantoftCenter for Clinical Research and Prevention, Bispebjerg and Frederiksberg University Hospital, 2400, Frederiksberg, Denmark.
Casper S PoulsenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Sofia K ForslundExperimental and Clinical Research Center, A Cooperation of Charité-Universitätsmedizin and the Max-Delbrück Center, 10117, Berlin, Germany.
Henrik VestergaardNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Torben HansenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark.
Susanne BrixDepartment of Biotechnology and Biomedicine, Technical University of Denmark, 2800, Kongens Lyngby, Denmark.
Annette OturaiDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, 2600, Glostrup, Denmark.
Per Soelberg SørensenDanish Multiple Sclerosis Center, Department of Neurology, Copenhagen University Hospital - Rigshospitalet, 2600, Glostrup, Denmark.
Stanislav D EhrlichUniversité Paris-Saclay, INRAE, MGP, 78350, Jouy-en-Josas, France.
Oluf PedersenNovo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Science, University of Copenhagen, 2200, Copenhagen, Denmark. oluf@sund.ku.dk.ORCID 0000-0002-3321-3972
University of Copenhagen · DKUniversité Paris-Saclay · FRCopenhagen University Hospital · DKFrederiksberg Hospital · DKMax Delbrück Center · DENovo Nordisk Foundation · DKTechnical University of Denmark · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMultiple sclerosis is a chronic immune-mediated disease of the brain and spinal cord resulting in physical and cognitive impairment in young adults. It is hypothesized that a disrupted bacterial and viral gut microbiota is a part of the pathogenesis mediating disease impact through an altered gut microbiota-brain axis. The aim of this study is to explore the characteristics of gut microbiota in multiple sclerosis and to associate it with disease variables, as the etiology of the disease remains only partially known.

methodsHere, in a case-control setting involving 148 Danish cases with multiple sclerosis and 148 matched healthy control subjects, we performed shotgun sequencing of fecal microbial DNA and associated bacterial and viral microbiota findings with plasma cytokines, blood cell gene expression profiles, and disease activity.

resultsWe found 61 bacterial species that were differentially abundant when comparing all multiple sclerosis cases with healthy controls, among which 31 species were enriched in cases. A cluster of inflammation markers composed of blood leukocytes, CRP, and blood cell gene expression of IL17A and IL6 was positively associated with a cluster of multiple sclerosis-related species. Bacterial species that were more abundant in cases with disease-active treatment-naïve multiple sclerosis were positively linked to a group of plasma cytokines including IL-22, IL-17A, IFN-β, IL-33, and TNF-α. The bacterial species richness of treatment-naïve multiple sclerosis cases was associated with number of relapses over a follow-up period of 2 years. However, in non-disease-active cases, we identified two bacterial species, Faecalibacterium prausnitzii and Gordonibacter urolithinfaciens, whose absolute abundance was enriched. These bacteria are known to produce anti-inflammatory metabolites including butyrate and urolithin. In addition, cases with multiple sclerosis had a higher viral species diversity and a higher abundance of Caudovirales bacteriophages.

conclusionsConsiderable aberrations are present in the gut microbiota of patients with multiple sclerosis that are directly associated with blood biomarkers of inflammation, and in treatment-naïve cases bacterial richness is positively associated with disease activity. Yet, the finding of two symbiotic bacterial species in non-disease-active cases that produce favorable immune-modulating compounds provides a rationale for testing these bacteria as adjunct therapeutics in future clinical trials.

Indexed as

Gastrointestinal MicrobiomeMicrobiotaMultiple SclerosisBacteriaCytokinesFecesHumansInflammationYoung AdultCytokinesFaecalibacterium prausnitziiGordonibacter urolithinfaciensGut microbiotaMultiple sclerosisShotgun sequencing

Identifiers

PMID36604748
PMCPMC9814178
OpenAlexW4313574624

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.